Australia is closely awaiting the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, this https://puffla269079.1blogtheme.com/61485485/retatrutide-australia-a-promising-breakthrough-for-obesity-treatment